ClinicalTrials.gg
CompletedNCT02848326Updated Dec 6, 2018Results posted

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

A Phase 2/3 interventional study of Atogepant and Placebo-matching Atogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 75 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-06.

Sponsored by Allergan (part of AbbVie) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
834
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
4th of 21
834 · median 468
Started
2016
the only one that year
Phase 2/3
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 4th largest by enrollment, is the only one that started in 2016, is the only one in phase 2/3, and was the 1st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

03

Conditions studied

  • Migraine, With or Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has at least a 1-year history of migraine with or without aura
  • Age of the patient at the time of migraine onset \< 50 years
  • History of 4 to 14 migraine days (migraine/probable migraine headache days) per month on average in the 3 months prior to Visit 1 in the Investigator's judgment
  • Demonstrated compliance with e-diary

Exclusion criteria

Exclusion Criteria:

  • Has a history of migraine accompanied by diplopia or decreased level of consciousness and retinal migraine
  • Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • Difficulty distinguishing migraine headache from other headaches
  • Has a history of in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Has a history of gastric or small intestinal surgery, or has a disease that causes malabsorption
  • Has a history of hepatitis within previous 6 months
  • Usage of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, non-steroidal anti-inflammatory drugs [NSAIDs], acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1
  • Pregnant or nursing females
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
834 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.

    Drug: Placebo-matching Atogepant

  • Experimental
    Atogepant 10 mg QD

    Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.

    Drug: Atogepant · Drug: Placebo-matching Atogepant

  • Experimental
    Atogepant 30 mg QD

    Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.

    Drug: Atogepant · Drug: Placebo-matching Atogepant

  • Experimental
    Atogepant 30 mg BID

    Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.

    Drug: Atogepant

  • Experimental
    Atogepant 60 mg QD

    Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.

    Drug: Atogepant · Drug: Placebo-matching Atogepant

  • Experimental
    Atogepant 60 mg BID

    Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.

    Drug: Atogepant

Interventions

  • Atogepant capsule.

    Also known as: AGN-241689

  • DrugPlacebo-matching Atogepant

    Placebo-matching atogepant capsule.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4- week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.

    Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12

Secondary outcomes

  1. Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration and acute symptomatic medication use. The 4-week (monthly) headache days was defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.

    Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12

  2. Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days=total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

    Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12

  3. Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period

    Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The 4-week (monthly) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. A negative change from Baseline indicates improvement.

    Time frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12

07

Results

Posted Dec 6, 2018

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Started186941851878993
Safety population: received study drug186931831868691
Completed148801491647073
Not completed381436231920
Withdrew: Adverse event5411657
Withdrew: Withdrawal of consent2069696
Withdrew: Lost to follow-up5111723
Withdrew: Pregnancy001101
Withdrew: Protocol violation434233
Withdrew: Non-compliance with study drug400100
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestonePlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Started161841561697782
Completed157831531697677
Not completed413015
Withdrew: Withdrawal of consent011002
Withdrew: Lost to follow-up402013

Outcome measures

PrimaryChange From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4- week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.

Time frame:
Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Reported as:
Least squares mean · migraine days per month
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
migraine days per monthPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period-2.85 ± 0.23-4.00 ± 0.32-3.76 ± 0.23-3.55 ± 0.23-4.23 ± 0.35-4.14 ± 0.33
Statistical analysis
  • Placebo vs Atogepant 10 mg QD · MMRM · p = 0.0039 (Mixed-effects model for repeated measures (MMRM) model included baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.15 · 95% CI -1.93 to -0.37
  • Placebo vs Atogepant 30 mg QD · MMRM · p = 0.0056 (MMRM model included baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -0.91 · 95% CI -1.55 to -0.27
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0325 (MMRM model included baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -0.70 · 95% CI -1.35 to -0.06
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0010 (MMRM model included baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.39 · 95% CI -2.21 to -0.56
  • Placebo vs Atogepant 60 mg BID · MMRM · p = 0.0016 (MMRM model included baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.29 · 95% CI -2.09 to -0.49
SecondaryChange From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration and acute symptomatic medication use. The 4-week (monthly) headache days was defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Negative change from Baseline indicates improvement.

Time frame:
Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Reported as:
Least squares mean · headache days per month
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period
headache days per monthPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period-2.93 ± 0.25-4.31 ± 0.35-4.17 ± 0.25-3.86 ± 0.25-4.23 ± 0.38-4.32 ± 0.36
Statistical analysis
  • Placebo vs Atogepant 10 mg QD · MMRM · p = 0.0014 (MMRM model included baseline monthly headache days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.38 · 95% CI -2.23 to -0.54
  • Placebo vs Atogepant 30 mg QD · MMRM · p = 0.0005 (MMRM model included baseline monthly headache days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.24 · 95% CI -1.94 to -0.55
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0087 (MMRM model included baseline monthly headache days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -0.94 · 95% CI -1.64 to -0.24
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0044 (MMRM model included baseline monthly headache days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.30 · 95% CI -2.20 to -0.41
  • Placebo vs Atogepant 60 mg BID · MMRM · p = 0.0017 (MMRM model included baseline monthly headache days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.39 · 95% CI -2.26 to -0.53
SecondaryPercentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration and acute symptomatic medication use. The 4-week migraine days=total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

Time frame:
Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
percentage of participantsPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period40.457.653.352.058.262.1
Statistical analysis
  • Placebo vs Atogepant 10 mg QD · GLMM for repeated measures · p = 0.0617 (Generalized linear mixed model (GLMM) for repeated measures with fixed factors(treatment group,visit), covariates(baseline migraine days), interactions(treatment group;baseline migraine days by visit) with an unstructured covariance matrix.) · Odds ratio (or): 1.50 · 95% CI 0.98 to 2.31
  • Placebo vs Atogepant 30 mg QD · GLMM for repeated measures · p = 0.0369 (GLMM for repeated measures with fixed factors (treatment group, visit), covariates (baseline migraine days), interactions (treatment group by visit; baseline migraine days by visit) with an unstructured covariance matrix.) · Odds ratio (or): 1.46 · 95% CI 1.02 to 2.08
  • Placebo vs Atogepant 60 mg QD · GLMM for repeated measures · p = 0.0512 (GLMM for repeated measures with fixed factors (treatment group, visit), covariates (baseline migraine days), interactions (treatment group by visit; baseline migraine days by visit) with an unstructured covariance matrix.) · Odds ratio (or): 1.42 · 95% CI 1.00 to 2.03
  • Placebo vs Atogepant 30 mg BID · GLMM for repeated measures · p = 0.0113 (GLMM for repeated measures with fixed factors (treatment group, visit), covariates (baseline migraine days), interactions (treatment group by visit; baseline migraine days by visit) with an unstructured covariance matrix.) · Odds ratio (or): 1.83 · 95% CI 1.15 to 2.91
  • Placebo vs Atogepant 60 mg BID · GLMM for repeated measure · p = 0.0019 (GLMM for repeated measures with fixed factors (treatment group, visit), covariates (baseline migraine days), interactions (treatment group by visit; baseline migraine days by visit) with an unstructured covariance matrix.) · Odds ratio (or): 2.03 · 95% CI 1.30 to 3.18
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period

Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The 4-week (monthly) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. A negative change from Baseline indicates improvement.

Time frame:
Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Reported as:
Least squares mean · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period
acute medication use days per monthPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period-2.42 ± 0.21-3.71 ± 0.29-3.86 ± 0.20-3.53 ± 0.21-3.77 ± 0.31-3.64 ± 0.29
Statistical analysis
  • Placebo vs Atogepant 10 mg QD · MMRM · p = 0.0002 (MMRM model included baseline monthly acute medication use days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.30 · 95% CI -1.99 to -0.60
  • Placebo vs Atogepant 30 mg QD · MMRM · p = <0.0001 (MMRM model included baseline monthly acute medication use days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.44 · 95% CI -2.01 to -0.87
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0001 (MMRM model included baseline monthly acute medication use days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.11 · 95% CI -1.68 to -0.54
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0003 (MMRM model included baseline monthly acute medication use days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.35 · 95% CI -2.08 to -0.62
  • Placebo vs Atogepant 60 mg BID · MMRM · p = 0.0007 (MMRM model included baseline monthly acute medication use days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and baseline-by-visit as interaction terms.) · Least squares mean difference: -1.22 · 95% CI -1.93 to -0.52

Adverse events

Collected over Up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/186 (0%)2/186 (1.1%)36/186 (19.4%)
Atogepant 10 mg QD0/93 (0%)1/93 (1.1%)17/93 (18.3%)
Atogepant 30 mg QD0/183 (0%)2/183 (1.1%)47/183 (25.7%)
Atogepant 60 mg QD0/186 (0%)2/186 (1.1%)52/186 (28%)
Atogepant 30 mg BID0/86 (0%)0/86 (0%)21/86 (24.4%)
Atogepant 60 mg BID0/91 (0%)0/91 (0%)26/91 (28.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
CholecystitisHepatobiliary disorders0/1861/930/1830/1860/860/91
UreteritisInfections and infestations0/1860/931/1830/1860/860/91
MigraineNervous system disorders0/1860/931/1830/1860/860/91
AbortionPregnancy, puerperium and perinatal conditions0/1860/930/1831/1860/860/91
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1860/930/1830/1860/860/91
OverdosePsychiatric disorders0/1860/930/1831/1860/860/91
Major depressionPsychiatric disorders0/1860/930/1831/1860/860/91
UreterolithiasisRenal and urinary disorders1/1860/930/1830/1860/860/91
Most frequent other events
Most frequent other events
EventPlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BID
NauseaGastrointestinal disorders9/1865/9313/18321/1867/869/91
FatigueGeneral disorders6/1861/933/1835/1862/869/91
Upper respiratory tract infectionInfections and infestations14/1866/9313/1839/1864/866/91
NasopharyngitisInfections and infestations4/1863/9310/18314/1861/861/91
ConstipationGastrointestinal disorders4/1862/9310/1839/1863/866/91
Blood creatine phosphokinase increasedInvestigations2/1863/933/1832/1865/862/91

Baseline characteristics

Safety Population included all participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)PlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BIDTotal
Mean40.5 ± 11.739.4 ± 12.441.0 ± 13.640.4 ± 11.738.5 ± 11.239.7 ± 11.940.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BIDTotal
Female154821661567383714
Male32111730138111
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BIDTotal
White137691451337371628
Black or African American452029441119168
Asian1123108
American Indian or Alaska Native3012006
Native Hawaiian/Other Pacific Islander0020002
Multiple Races03441113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BIDTotal
Hispanic or Latino291532251313127
Not Hispanic or Latino157781511617378698
Migraine Days (Migraine/Probable Migraine Headache Days)
Migraine Days (Migraine/Probable Migraine Headache Days)(migraine days per month)PlaceboAtogepant 10 mg QDAtogepant 30 mg QDAtogepant 60 mg QDAtogepant 30 mg BIDAtogepant 60 mg BIDTotal
Mean7.81 ± 2.517.63 ± 2.517.64 ± 2.377.74 ± 2.597.38 ± 2.437.62 ± 2.567.67 ± 2.49
08

Study locations

75 sites
  • Achieve Clinical Research
    Birmingham, Alabama 35216, United States
  • Radiant Research, Inc.
    Chandler, Arizona 85224, United States
  • The Research Center of Southern California, LLC
    Carlsbad, California 92011, United States
  • Neuro-Pain Medical Center, Inc
    Fresno, California 93710, United States
  • Irvine Center for Clinical Research
    Irvine, California 92618, United States
  • Downtown LA Research Center, Inc.
    Los Angeles, California 90017, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • Diablo Clinical Research Inc
    Walnut Creek, California 94598, United States
  • Advanced Neurosciences Research
    Fort Collins, Colorado 80528, United States
  • Hartford Headache Center
    East Hartford, Connecticut 06118, United States
  • Associated Neurologists of Southern Connecticut, P. C.
    Fairfield, Connecticut 06824, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • The George Washington University
    Washington, District of Columbia 20037, United States
  • Clinical Research South Florida
    Coral Gables, Florida 33134, United States
  • Infinity Clinical Research
    Hollywood, Florida 33021, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions Inc
    Jacksonville, Florida 32256, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Suncoast Research
    Miami, Florida 33135, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Palm Beach Neurological Center / Advanced Research Consultants, Inc.
    Palm Beach Gardens, Florida 33410, United States
  • Suncoast Neuroscience Associates, Inc.
    Saint Petersburg, Florida 33713, United States
  • Infinity Clinical Research LLC
    Sunrise, Florida 33351, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Neurology Research Institute Palm Beach
    West Palm Beach, Florida 33407, United States
  • Institute for Advanced Medical Research
    Alpharetta, Georgia 30005, United States
  • Radiant Research
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology
    Sandy Springs, Georgia 30328, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Northwest Clinical Trials, Inc.
    Boise, Idaho 83704, United States
  • Healthcare Research Network II, LLC
    Blue Island, Illinois 60406, United States
  • Rowe Neurology Institute
    Lenexa, Kansas 66214, United States
  • Boston Clinical Trials Inc
    Boston, Massachusetts 02131, United States
  • Northeast Medical Research Associates, Inc.
    North Dartmouth, Massachusetts 02747, United States
  • Medvadis Research Corporation
    Watertown, Massachusetts 02472, United States
  • New England Regional Headache Center
    Worcester, Massachusetts 01605, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Mercy Research
    Springfield, Missouri 65806, United States
  • Clinvest
    Springfield, Missouri 65807, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Renown Institute for Neuroscience
    Reno, Nevada 89502, United States
  • Hassman Research Institute - NJ
    Berlin, New Jersey 08009, United States
  • Amici Clinical Research
    Warren, New Jersey 07059, United States
  • DENT Neurosciences Research Center
    Amherst, New York 14226, United States
  • Radiant Research, Inc.
    Jamaica, New York 11432, United States
  • Carolina Headache Institute
    Durham, North Carolina 27713, United States
  • Wake Research Associates LLC
    Raleigh, North Carolina 27612, United States
  • Ohio Clinical Research, LLC
    Willoughby Hills, Ohio 44094, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon 97301, United States
  • Lehigh Center For Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Cns Healthcare
    Memphis, Tennessee 38119, United States
  • Nashville Neuroscience Group
    Nashville, Tennessee 37203, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • DermResearch Inc
    Austin, Texas 78759, United States
  • DiscoveResearch, Inc.
    Bryan, Texas 77802, United States
  • Synexus US, L.P. Formally known as Texas Pharmaceutical Research, LP, DBA Research Across America
    Dallas, Texas 75234, United States
  • Central Texas Neurology Consultant
    Round Rock, Texas 78681, United States
  • Radiant Research, San Antonio Center for Clinical Research
    San Antonio, Texas 78229, United States
  • Road Runner Research LTD
    San Antonio, Texas 78258, United States
  • ClinPoint Trials, LLC
    Waxahachie, Texas 75165, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Women's Clinical Research Center
    Seattle, Washington 98105, United States
  • Kingfisher Cooperative, LLC
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9. Erratum In: Lancet Neurol. 2020 Nov;19(11):e10. doi: 10.1016/S1474-4422(20)30350-1. PubMed 32822633 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Apr 2018, 18 months.

Results were first posted in Dec 2018, 8 months after primary completion.

Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 18 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Jul 28, 2016
StartActual
Sep 6, 2016
Primary completionActual
Apr 2, 2018
CompletionActual
Apr 23, 2018
Results first posted
Dec 6, 2018
Last update
Dec 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02848326
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Sep 6, 2016
Primary completion
Apr 2, 2018
Completion
Apr 23, 2018
Results posted
Dec 6, 2018
Last update
Dec 6, 2018

Study contacts

Joel Trugman, MD
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion